Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Salarius Pharmaceuticals Inc (SLRX)

Salarius Pharmaceuticals Inc (SLRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,018
  • Shares Outstanding, K 1,441
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,540 K
  • EBIT $ -5 M
  • EBITDA $ -5 M
  • 60-Month Beta 0.93
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.69

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3331 +5.02%
on 11/15/24
2.0400 -31.37%
on 10/22/24
-0.4200 (-23.08%)
since 10/21/24
3-Month
1.2600 +11.11%
on 10/14/24
2.3500 -40.43%
on 10/18/24
-0.5600 (-28.57%)
since 08/21/24
52-Week
1.2600 +11.11%
on 10/14/24
7.2720 -80.75%
on 11/30/23
-3.9440 (-73.80%)
since 11/21/23

Most Recent Stories

More News
Salarius: Q3 Earnings Snapshot

Salarius: Q3 Earnings Snapshot

SLRX : 1.4074 (+0.53%)
Salarius: Q2 Earnings Snapshot

Salarius: Q2 Earnings Snapshot

SLRX : 1.4074 (+0.53%)
Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Multiple development and data milestones expected from seclidemstat and SP-3164 programs in 2H22 Conference call and webcast today at 11:00 a.m. ET...

SLRX : 1.4074 (+0.53%)
Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Clinical Trial Now Expands to Fifteen U.S. Trial Sites ...

SLRX : 1.4074 (+0.53%)
Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement

HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies...

SLRX : 1.4074 (+0.53%)
VNRX : 0.8326 (+2.79%)
Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022

Conference Call and Live Audio Webcast Scheduled for 11:00 a.m. ET...

SLRX : 1.4074 (+0.53%)
Salarius Pharmaceuticals to Participate in BIO International Convention 2022

HOUSTON, Texas, June 09, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing...

SLRX : 1.4074 (+0.53%)
Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential...

SLRX : 1.4074 (+0.53%)
Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results

Salarius Successfully Completes SP-3164 Pre-IND Meeting Process with FDA Advancing multiple drug development programs, led by SP-3164 in targeted protein...

SLRX : 1.4074 (+0.53%)
Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration

Salarius planning for SP-3164 IND Application Submission in 2023...

SLRX : 1.4074 (+0.53%)

Business Summary

Salarius Pharmaceuticals Inc. is a clinical-stage oncology company. It develops therapies for the treatment of cancers. The company's lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and...

See More

Key Turning Points

3rd Resistance Point 1.5727
2nd Resistance Point 1.5263
1st Resistance Point 1.4632
Last Price 1.4074
1st Support Level 1.3537
2nd Support Level 1.3073
3rd Support Level 1.2442

See More

52-Week High 7.2720
Fibonacci 61.8% 4.9754
Fibonacci 50% 4.2660
Fibonacci 38.2% 3.5566
Last Price 1.4074
52-Week Low 1.2600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar